TrialBlood advances2021

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

Bob Löwenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.